Evidence Tier: Phase 1-2 (development discontinued) — CJC-1295 is a synthetic analog of growth hormone-releasing hormone (GHRH) with enhanced half-life. The DAC (Drug Affinity Complex) variant binds to albumin for extended duration.
Overview
CJC-1295 is a synthetic 30-amino acid peptide analog of GHRH(1-29) (also known as Modified GRF 1-29 or Mod GRF 1-29 in its non-DAC form). The peptide was developed by ConjuChem Biotechnologies with modifications at positions 2, 8, 15, and 27 to resist enzymatic degradation.
Key Variants
- CJC-1295 with DAC: Includes a Drug Affinity Complex that binds to serum albumin, extending half-life to 6-8 days. Produces sustained, non-pulsatile GH elevation.
- CJC-1295 without DAC (Mod GRF 1-29): Shorter half-life (~30 minutes), produces more physiological pulsatile GH release.
Clinical Data
Phase 1-2 trials demonstrated:
- 2-10 fold increase in GH levels sustained for 6+ days (with DAC)
- 1.5-3 fold increase in IGF-1 levels sustained for 9-11 days (with DAC)
- Well-tolerated at doses up to 60-90 mcg/kg
Development was discontinued following an unrelated death in one trial participant. No causal relationship was established, but ConjuChem ceased development.
References
- Teichman SL, et al. "Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults." J Clin Endocrinol Metab. 2006;91(3):799-805.
Research Disclaimer
This article is compiled from peer-reviewed research and publicly available scientific literature. It is intended for educational and informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional before making health-related decisions.